.Plovier H. Everard A. Druart C. Depommier C. Van Hul M. Geurts L. Chilloux J. Ottman N. Duparc T. Lichtenstein L. Myridakis A. Delzenne N.M. Klievink J. Bhattacharjee A. van der Ark K.C.

ReviewInflammageing and metaflammation The yin and yang of type 2 diabetesFrancesco Prattichizzo Valeria De Nigris Rosangela Spiga Elettra Mancuso Lucia La Sala Roberto Antonicelli Roberto Testa Antonio Domenico Procopio Fabiola OlivieriAntonio Cerielloa Department of Cardiovascular Research IRCCS MultiMedica Milan MI Italyb Diabetes and Obesity Research Laboratory Institut d'Investigacions Biomediques August Pi I Sunyer IDIBAPS Barcelona Spainc Cardiology Unit Italian National Research Center on Ageing INRCA-IRCCS Ancona Italyd Clinical Laboratory and Molecular Diagnostics INRCA-IRCCS National Institute Ancona Italye Department of Clinical and Molecular Sciences DISCLIMO Universita Politecnica delle Marche Ancona Italyf Center of Clinical Pathology and Innovative Therapy National Institute INRCA-IRCCS Ancona Italyg CIBER de Diabetes y Enfermedades Metabolicas Asociadas CIBERDEM SpainA R T I C L E I N F O KeywordsType 2 diabetes Metaflammation Inflammageing Immune system Immunometabolism SenescenceSASPEpigenetic alterations microRNA Mediterranean diet Fasting regimen MicrobiotaAntihyperglycaemic agent Hyperglycaemic memory Oxidative stressA B S T R A C T Type 2 diabetes mellitus T2DM is characterised by chronic low-grade inflammation recently referred to as 'metaflammation' a relevant factor contributing to the development of both diabetes and its complications.

.Qin J. Li Y. Cai Z. Li S. Zhu J. Zhang F. Liang S. Zhang W. Guan Y. Shen D.Peng Y. Zhang D. Jie Z. Wu W. Qin Y. Xue W. Li J. Han L. Lu D. Wu P.Dai Y.

Helman A. Klochendler A. Azazmeh N. Gabai Y. Horwitz E. Anzi S. Swisa A. Condiotti R. Granit R.Z.

Moreno-Asso A. Castano C. Grilli A. Novials A. Servitja J.M.

Selective removal of harmful cells may eventually revolutionise the management of patients with diabetes by possibly allowing for interventions in the patients in whom age and obesity are the main determinants of T2DM even in long-lasting dis- ease considering the chronic nature of both senescent-cell accumula-tion and T2DM .

However the accumulated data definitely suggest that the active life- style is one of the best approaches to management of low-grade in- flammation preventing T2DM development and CVDs and promoting healthy ageing .Anti-metaflammation activity of anti-hyperglycaemic medications showing a high clinical value in terms of prevention of T2DM complicationsMetforminMeta-analysis of long-marketed hypoglycaemic drugs and clinical trials of new anti-diabetic medications have revealed different out- comes between various compounds in relation to prevention of T2DM complications .

Vestergaard H. Hercog R. Igor Costea P. Kultima J.R. Li J. Jorgensen T. Levenez F. Dore J. Meta consortium H.I.T.

Brunak S. Raes J. Hansen T. Wang J. Ehrlich S.D.

Frystyk J. Dillon B. Evans G. Cuzick J. Jebb S.A. Martin B. Cutler R.G.

